Irena Marjanović, PhD, is a molecular biologist and physiologist with a research focus on medical genetics and elucidating the molecular basis of rare genetic diseases. She completed her studies at the Faculty of Biology of the University of Belgrade, majoring in Molecular Biology and Physiology, in 2010. She enrolled in doctoral studies at the Faculty of Biology, University of Belgrade, study program Molecular Biology, and defended her doctoral dissertation entitled "Identification of molecular genetic markers of the pathogenesis of acute myeloid leukemia" in 2018 at the Faculty of Biology, University of Belgrade. Irena Marjanović was employed at the Laboratory for Molecular Biomedicine (then the Laboratory for Molecular Hematology) in 2012 on the project of the Ministry of Science and Technological Development of the Republic of Serbia, project no. III 41004, entitled ''Rare diseases: molecular pathophysiology, diagnostic and therapeutic modalities and social, ethical and legal aspects''.
Dr. Irene Marjanović's interest is in elucidating the molecular basis of rare genetic diseases, primarily in the field of molecular hematology, including hematological malignancies - acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL) and lymphomas.
Dr. Irene Marjanović's doctoral thesis was the first in Serbia to use the Next Generation Sequencing (NGS) methodology to determine the mutational profiles of patients with AML, so the continuation of her research after the doctorate is devoted to the application of next-generation sequencing technology in the analysis of the mutational profiles of other rare diseases - pediatric tumors of the central nervous system, epilepsy, aplastic anemia. With her work, Dr. Irena Marjanović is active in several scientific disciplines of molecular biology - biomedical research and molecular diagnostics. By actively participating and working in the Center for the diagnosis of rare diseases at IMGGI and using new generation sequencing, which includes clinical exome sequencing (CES) and whole exome sequencing (WES) as well as mitochondrial DNA, she actively participates in the molecular genetic diagnosis of several rare diseases, among which are oncological diseases, hematological diseases, neurodevelopmental disorders, muscular, cardiac, neurological, ophthalmological and metabolic diseases. She is a member of several scientific societies and is engaged in domestic and international projects within her research group.
